Zevra Therapeutics, Inc.
HealthcareNASDAQ:ZVRA · NASDAQ Global Select
-$0.32 today
Vol 1.72M · Avg 1.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
53.8%
avg 46.5%
ROIC
-1.7%
avg -100.5%
ROA
29.2%
avg -76.8%
Analysis
ROE is currently the strongest return metric at 53.8% versus its period average of 46.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Neil F. McFarlane | President, Chief Executive Officer & Director | $1.16M | — | 53 | $387,225.00 | 0.66% |
Joshua Schafer | Chief Commercial Officer | $766,068.00 | — | 54 | $62,278.00 | 0.11% |
Rahsaan W. Thompson | Chief Legal Officer, Secretary & Compliance Officer | $753,334.00 | — | 55 | $48,125.00 | 0.08% |
Adrian Quartel FFPM | Chief Medical Officer | $705,132.00 | — | 65 | $22,667.00 | 0.04% |
Justin A. Renz | Chief Financial Officer & Treasurer | $704,073.00 | — | 54 | $0.00 | <0.01% |
Timothy J. Sangiovanni | Senior VP of Finance & Corporate Controller | — | — | 42 | $20,000.00 | 0.03% |
Alison Peters | Chief People Officer | — | — | — | — | — |
Tanya Hayden | Senior Vice President & Chief of Staff | — | — | 46 | — | — |
Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality | — | — | 59 | $20,000.00 | 0.03% |
Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Christopher Lauderback | Senior Vice President of Manufacturing | — | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$228,343.01
Sells
11
$1.68M
Net Sentiment
$1.45M
Net selling
Most Active
Thompson Rahsaan
3 transactions
1–10 of 14
Analysis
Insiders reported 3 buys worth $228,343.01 and 11 sells worth $1.68M over the last 12 months. That adds up to net selling of $1.45M. Thompson Rahsaan was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Niagen Bioscience Inc
NASDAQ:NAGE
$274.77M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages ZVRA?
Zevra Therapeutics, Inc. (ZVRA) lists 11 active executives. The top listed executive is Joshua Schafer, Chief Commercial Officer.
Are ZVRA insiders buying or selling?
Recent insider activity shows net buying of $13.09M.
Explore More
Continue the stock analysis
Jump to another research area for this company.